No abstract

Background: Though not common, maxillofacial osteosarcomas present a unique challenge in management due to a multitude of factors, such as difficulty in diagnosis and local complex anatomy, making surgical excision difficult as well as debate necessary on the usefulness of adjunct treatment modalities, such as chemotherapy and radiotherapy. Nonetheless, osteosarcomas are a significant health burden because of their high morbidity and mortality. Method: Retrospective cross-sectional study of records archived in the School of Dental Sciences, University of Nairobi. Results: 25 cases of maxillofacial sarcomas were seen over 26 years. Mean age of occurrence was 35.68 years with a preponderance for females (17 cases). The mandible was the most affected site, accounting for 18 cases. Discussion: The management of maxillofacial sarcomas in our setting presents significant challenges arising from multiple factors such as lack of standardised treatment protocol, late presentation of patients, diagnostic challenges and loss to follow-up.

Outcome of poor prognostic phenotype non-Hodgkin's lymphoma treatment in relation to human immunodeficiency virus serostatus Résultats du traitement du lymphome non-hodgkinien au phénotype à pronostic pauvre, associé au sérostatut du virus d'immunodéficience humaine (VIH)The abstract of this paper was published Abstract Background: The risk of developing aggressive phenotype non-Hodgkin's lymphomas is high among HIV infected individuals and is associated with worse prognosis than among non-HIV infected ones. Effective antiretroviral therapy has more recently been reported to greatly improve outcome among these patients. A retrospective review of treatment outcome for aggressive and highly aggressive phenotype non-Hodgkin's lymphoma patients was carried out. The objective was to compare outcome of treatment for poor prognosis subtypes of non-Hodgkin's lymphomas in relation to HIV-serostatus. The setting was Hurlingham Oncology clinic, a private oncology clinic in Nairobi, Kenya. The main study endpoints were complete remission rate and overall survival.

No abstract